Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25

Core Insights - Daxor Corporation will showcase its next-generation Blood Volume Analysis (BVA) diagnostic system at the MedAxiom Cardiovascular Transforum Fall'25 Conference, which is a key event for cardiovascular organizational performance solutions [1][2] - The launch of the new BVA system is expected to enhance sales momentum and strengthen market leadership by addressing critical issues such as hospital readmissions and resource optimization [2] - Daxor is focused on solving the healthcare challenge of accurately measuring blood volume, which is crucial for improving patient care and reducing hospital stays, particularly for conditions like heart failure [3] Company Overview - Daxor Corporation is recognized as a leader in blood volume measurement technology, with a patented, FDA-cleared BVA diagnostic system that provides real-time, precise data [3] - The company has 50 years of experience in the industry and operates a state-of-the-art manufacturing facility in the U.S., which supports its market expansion efforts [3] - Daxor's technology aims to empower clinicians to make individualized treatment decisions, thereby improving patient outcomes and enhancing efficiencies in value-based healthcare [3]